| pubmed-article:1884902 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1884902 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1884902 | lifeskim:mentions | umls-concept:C0011849 | lld:lifeskim |
| pubmed-article:1884902 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:1884902 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:1884902 | lifeskim:mentions | umls-concept:C1522577 | lld:lifeskim |
| pubmed-article:1884902 | lifeskim:mentions | umls-concept:C0023983 | lld:lifeskim |
| pubmed-article:1884902 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1884902 | pubmed:dateCreated | 1991-10-8 | lld:pubmed |
| pubmed-article:1884902 | pubmed:abstractText | In the Canadian/European randomized controlled study on cyclosporin A (CsA) in recent onset Type 1 (insulin-dependent) diabetes, treatment with the immunosuppressive drug had increased and maintained Beta-cell function and clinical remission during the first 12 months. Following discontinuation of the study drug and double-blinding after a mean of 13.8 months former CsA patients doubled the daily insulin dose within 6 months reaching the level of former placebo patients. The difference in Beta-cell function between the two groups was also lost. Metabolic control (HbA1c) was transiently worse in the former CsA group. Adverse effects of cyclosporin A on systolic blood pressure, haemoglobin levels, serum potassium and creatinine levels also remitted during that time. We conclude that treatment with cyclosporin A for a mean of 13.8 months had no long-lasting effect on the course of Type 1 diabetes persisting beyond drug discontinuation. | lld:pubmed |
| pubmed-article:1884902 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1884902 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1884902 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1884902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1884902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1884902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1884902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1884902 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1884902 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:1884902 | pubmed:issn | 0012-186X | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:StandlEE | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:SchernthanerG... | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:KakV KVK | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:HamerRR | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:MartinSS | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:NerupJJ | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:KoivistoV AVA | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:GrantR ERE | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:DupréJJ | lld:pubmed |
| pubmed-article:1884902 | pubmed:author | pubmed-author:McArthurRR | lld:pubmed |
| pubmed-article:1884902 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1884902 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:1884902 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1884902 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1884902 | pubmed:pagination | 429-34 | lld:pubmed |
| pubmed-article:1884902 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:meshHeading | pubmed-meshheading:1884902-... | lld:pubmed |
| pubmed-article:1884902 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1884902 | pubmed:articleTitle | Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. | lld:pubmed |
| pubmed-article:1884902 | pubmed:affiliation | Diabetes Research Institute, University of Düsseldorf, FRG. | lld:pubmed |
| pubmed-article:1884902 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1884902 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1884902 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1884902 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1884902 | lld:pubmed |
